SCHEMBL971457

SCHEMBL971457

CCCc1nc(C)c2c(N)nc3ccccc3n12

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TLR7 Q9NYK1 6/20 0.52
PDE10A Q9Y233 5/20 0.51
MAPT P10636 2/20 0.45
LMNA P02545 1/20 0.45
ADORA3 P0DMS8 1/20 0.44
ADORA2A P29274 1/20 0.44
ADORA1 P30542 1/20 0.44
PDE2A O00408 2/20 0.43
PDE5A O76074 2/20 0.43
PDE4A P27815 2/20 0.43
PDE4D Q08499 2/20 0.43
PDE7A Q13946 2/20 0.43
PDE3A Q14432 2/20 0.43
PDE7B Q9NP56 2/20 0.43
PDE11A Q9HCR9 1/20 0.43
TSHR P16473 1/20 0.43
HTT P42858 1/20 0.42
POLB P06746 1/20 0.42
ALDH1A1 P00352 1/20 0.42
PDE6D O43924 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL970412 0.89 PDE10A (0.52) TLR7PDE10AMAPTADORA3ADORA2A
SCHEMBL971822 0.88 PDE10A (0.63) TLR7PDE10AMAPTLMNAPDE2A
SCHEMBL3660862 0.86 PDE10A (0.46) TLR7PDE10AMAPTLMNAADORA3
SCHEMBL968994 0.83 PDE10A (0.51) TLR7PDE10AMAPTLMNAPDE2A
SCHEMBL969580 0.82 PDE10A (0.46) PDE10APDE2APDE5APDE4APDE4D
SCHEMBL970788 0.80 RPS6KA5 (0.47) TLR7PDE10APDE2APDE5APDE4A
SCHEMBL970200 0.80 PDE10A (0.49) PDE10APDE2APDE5APDE4APDE4D
SCHEMBL972979 0.76 PDE10A (0.57) PDE10AMAPTPDE2APDE5APDE4A
SCHEMBL971191 0.74 PDE2A (0.41) PDE10APDE2APDE5APDE4APDE4D
SCHEMBL14765127 0.71 PDE2A (0.53) PDE10APDE2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2225248-A1 ARYL AND HETEROARYL FUSED IMIDAZO[1,5-A]PYRAZINES AS INHIBITORS OF PHOSPHODIESTERASE 10 Wyeth LLC (US) 2010-09-08 EP claimed
WO-2009070584-A1 ARYL AND HETEROARYL FUSED IMIDAZO[1,5-A]PYRAZINES AS INHIBITORS OF PHOSPHODIESTERASE 10 WYETH (US) 2009-06-04 WO claimed
US-20090143367-A1 ARYL AND HETEROARYL FUSED IMIDAZO[1,5-a]PYRAZINES AS INHIBITORS OF PHOSPHODIESTERASE 10 ELBION GMBH (DE) 2009-06-04 US claimed
US-7875618-B2 8-chloro-3,4-dimethyl-1-(2- methylphenyl)imidazo[1,5- a]quinoxaline; inhibitors of phosphodiesterase 10; for treatment of central nervous system disorders (cognitive deficits, social phobia, reduced vigilance, obesity and psychosis) WYETH (US) 2011-01-25 US disclosed
EP-2225248-A1 ARYL AND HETEROARYL FUSED IMIDAZO[1,5-A]PYRAZINES AS INHIBITORS OF PHOSPHODIESTERASE 10 Wyeth LLC (US) 2010-09-08 EP disclosed
WO-2009070584-A1 ARYL AND HETEROARYL FUSED IMIDAZO[1,5-A]PYRAZINES AS INHIBITORS OF PHOSPHODIESTERASE 10 WYETH (US) 2009-06-04 WO disclosed
US-20090143367-A1 ARYL AND HETEROARYL FUSED IMIDAZO[1,5-a]PYRAZINES AS INHIBITORS OF PHOSPHODIESTERASE 10 ELBION GMBH (DE) 2009-06-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143367-A1 ARYL AND HETEROARYL FUSED IMIDAZO[1,5-a]PYRAZINES AS INHIBITORS OF PHOSPHODIESTERASE 10 PDE12, PDE5A, PDE10A TLR7 3098/4885PDE10A 3/4885MAPT 3499/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.